Title: Roles of bone-derived hormones in type 2 diabetes and cardiovascular pathophysiology
Authors: Lin, XZ
Onda, DA
Yang, CH
Lewis, JR
Levinger, I
Loh, K
Issue Year: 2020
Publisher ELSEVIER
Series MOLECULAR METABOLISM:
Abstract Acute myeloid leukemia (AML) is an aggressive, often fatal hematopoietic malignancy.All-transretinoic acid (atRA), one of the first molecularly targeted drugs in oncology, has greatly improved the outcome of a subtype of AML, acute promyelocytic leukemia (APL). In contrast, atRA has so far provided little therapeutic benefit in the much larger group of patients with non-APL AML. Attempts to identify genetically or molecularly defined subgroups of patients that may respond to atRA have not yielded consistent results. Since AML is a stem cell-driven disease, understanding the effectiveness of atRA may require an appreciation of its impact on AML stem cells. Recent studies reported that atRA decreased stemness of AML with anFLT3-ITD mutation, yet increased it inAML1-ETOdriven orEVI1-overexpressing AML. This review summarizes the role of atRA in normal hematopoiesis and in AML, focusing on its impact on AML stem cells.
URI: https://publications.svi.edu.au/publications/7022
Other Identifiers 10.1016/j.molmet.2020.101040
Publication type Review